These results clearly demonstrate the difference in feasibility between predicting epitopes with and without information of an applicant antibody. drug discovery, drug design 1. Introduction In this paper, we outline the deep learning techniques that are starting to be applied to the field of antibody design and their results. We outline current challenges in three areas of antibody design: (1) modeling of structure from sequence, (2) prediction of protein interactions, and (3) identification of likely binding sites. We then touch around the deep learning techniques and algorithms that have been developed towards antibody design in each of these areas. As these three challenge areas have HSP70-1 analogues in the general protein space, we additionally describe deep learning approaches for similar problems among proteins more broadly, with the understanding that these approaches may be applicable to the narrower domain name of antibody engineering. We also describe the dataset and benchmarks available that could aid in the development and comparison of methods within this field. We conclude with a comparison of these methods and touch on future directions. Monoclonal antibody therapeutics have become an increasingly popular approach for drug development against targets and indications where small-molecule-based approaches have proven insufficient. Cefuroxime axetil With this increase in focus has come the creation Cefuroxime axetil of a number of new methods for improving and refining the antibody development pipeline. Innovations in constructing display libraries (phage and yeast) have accelerated the candidate discovery timeline and reduced the challenges associated with downstream development of therapeutic leads. A significant goal of current lead development research has been to reduce the necessity of downstream lead optimization steps such as improvements to the solubility and immunogenicity of the candidates, along with the mitigation of other developability concerns. Other research has expanded the mechanisms of action of potential antibody therapeutics by adding additional functional domains to create bispecific and Fc effector antibodies, and by exploring different constructs for their unique properties, such as single-chain variable fragments and camelid-derived nanobodies. While these in vitro innovations have shortened timelines and have improved different actions throughout of the development pipeline, there have been a new class of innovations surrounding the engineering and design of antibody candidates. These approaches attempt to harness advances in computational processing power to reduce the cost and increase the velocity of lead candidate generation. The advantages of an pipeline would include rapid and cheap scaling of candidate generation, the ability to develop antibodies against challenging antigens, and the application of rational design principles. In contrast to traditional methods of candidate generation such as hybridoma or phage display, an pipeline promises cheaper and faster drug development. However, conventional methods have yet to fully deliver on these promises. Here, we present deep-learning-based approaches that appear to demonstrate greater success than conventional methods with respect to the key challenges of computational antibody design. 2. Antibodies Antibodies are a type of protein produced Cefuroxime axetil as an immune response to invading pathogens. They consist of four chainstwo heavy chains and two light chains. The heavy chains include three constant domains and a variable domain name, while the light chains have just one constant domain name and one variable domain name. The variable domains contain the antibodys binding surface, or paratope. The paratope primarily consists of six distinct variable loopsthree around the light chain (loops L1, L2, and L3), and three around the heavy chain (loops H1, H2, and H3) (Physique 1). This region, also called the complementarity-determining region, or CDR, is what allows an antibody to bind a target with high specificity [1]. The area is usually large enough to accommodate many unique contacts, which is usually a part of what allows for such high specificityespecially as compared to typical small molecules, which are able to accommodate far fewer contacts and thus tend to have a greater number of side-effect-causing off-target interactions. The Cefuroxime axetil substantial degree of variation between the CDR loops is usually significant, as Cefuroxime axetil the diversity of antibodies is usually part of what makes them effective binders for such a wide range of targets [1]. Open in a separate window Physique 1 Schematic of antibody and ribbon diagram of variable region. The heavy chain (H) of the antibody is usually depicted in dark blue, while the light chain (L) is usually shown in light blue. Both chains show labels C for constant region and V for variable region. The complementarity-determining region (CDR) is usually shown as orange loops around the light chain and yellow loops around the heavy chain..